357262-90-9

Usage

Uses

Used in Pharmaceutical Industry:
4-BENZOYL-2-METHYL-1-[(7-OXIDO-1H-PYRROLO[2,3-B] PYRIDIN-3-YL)OXOACETYL]-PIPERAZINE is used as a pharmaceutical compound for its potential to interact with biological systems, offering possible applications in the development of new medications.
Used in Medicinal Research:
In the field of medicinal research, 4-BENZOYL-2-METHYL-1-[(7-OXIDO-1H-PYRROLO[2,3-B] PYRIDIN-3-YL)OXOACETYL]-PIPERAZINE serves as a candidate molecule for studying its interactions with biological targets, which may lead to the discovery of novel therapeutic agents.
Used in Drug Development:
4-BENZOYL-2-METHYL-1-[(7-OXIDO-1H-PYRROLO[2,3-B] PYRIDIN-3-YL)OXOACETYL]-PIPERAZINE is utilized in drug development processes to explore its potential as a precursor or building block for creating new pharmaceuticals with specific therapeutic effects.

InChI:InChI=1/C21H20N4O4/c1-14-13-23(20(27)15-6-3-2-4-7-15)10-11-24(14)21(28)18(26)17-12-22-19-16(17)8-5-9-25(19)29/h2-9,12,14,22H,10-11,13H2,1H3/t14-/m1/s1

Upstream product

• 357263-39-9 1-benzoyl-3-(R)-methylpiperazine 
• 357263-49-1 methyl α-oxo-1H-pyrrolo[2,3-b]pyridine-3-acetate 
• 75336-86-6 (2R)-methylpiperazine 
• 271-63-6 7-Azaindole 
• 93-58-3 benzoic acid methyl ester 
• 357262-60-3 (R)-1-(4-benzoyl-2-methylpiperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethane-1,2-dione 

Downstream Products

• 357262-96-5 4-benzoyl-2-(R)-methyl-1-[(4-nitro-7-oxido-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]piperazine 
• 357263-05-9 4-benzoyl-1-[(4-methoxy-7-oxido-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine 
• 357263-13-9 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine 

Relevant academic research and scientific papers

TARGETED BIFUNCTIONAL DEGRADERS

The present invention provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present invention provides bifunctional compounds that can be used to promote or enhance degradation of certain autoantibodies. In certain embodiments, treatment or management of a disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein or the autoantibody in the subject. Thus, in certain embodiments, administration of a compound of the invention to the subject removes or reduces the circulation concentration of the circulating protein or the autoantibody, thus treating, ameliorating, or preventing the disease and/or disorder. In certain embodiments, the circulating protein is TNF.

BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS

The present invention is directed to bifunctional small molecules which contain a circulating protein binding moiety (CPBM) linked through a linker group to a cellular receptor binding moiety (CRBM) which is a membrane receptor of degrading cell such as a hepatocyte or other degrading cell. In embodiments, the (CRBM) is a moiety which binds to asialoglycoprotein receptor (an asialoglycoprotein receptor binding moiety, or ASGPRBM) of a hepatocyte. In additional embodiments, the (CRBM) is a moiety which binds to a receptor of other cells which can degrade proteins, such as a LRP1, LDLR, FcyRI, FcRN, Transferrin or Macrophage Scavenger receptor. Pharmaceutical compositions based upon these bifunctional small molecules represent an additional aspect of the present invention. These compounds and/or compositions may be used to treat disease states and conditions by removing circulating proteins through degradation in the hepatocytes or macrophages of a patient or subject in need of therapy. Methods of treating disease states and/or conditions in which circulating proteins are associated with the disease state and/or condition are also described herein.

Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R) -methylpiperazine (BMS-378806): A novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions

Indole derivative 1 interferes with the interaction of the HIV surface protein gp120 with the host cell receptor CD4. The 4-fluoro derivative 2 exhibited markedly enhanced potency and was bioavailable in the rat, dog, and cynomolgus monkey when administered orally as a solution formulation. However, aqueous suspensions of 2 were poorly bioavailable, indicative of dissolution-limited absorption. The 7-azaindole derivative 3, BMS-378806, exhibited improved pharmaceutical properties while retaining the HIV-1 inhibitory profile of 2.